TLR7 and neoplasm: Baharom et al. applied a self-assembling nanoparticle vaccine that linked neoantigen peptides to a Toll-like receptor 7/8 agonist (SNP-7/8a) to induce a higher proportion of CD8+PD-1+TCF1+ Texprog, resulting in a superior antitumor response in combination with a PD-L1 blockade.33 In addition, Ptpn2 deletion in CD8+ T cells enhanced the generation and cytotoxicity of TCF1−Texterm, promoted tumor control, and improved PD-1 checkpoint blockade responses to B16 tumors.34